Copertina

Diagnosis and management of neuroendocrine prostate cancer

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Ivan de Kouchkovsky, Emily Chan, Charles Schloss, Christian Poehlein, Rahul Aggarwal
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	The Prostate
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

L1CAM mediates neuroendocrine phenotype acquisition in prostate cancer cells
di: Chia‐Ling Hsieh, et al.
Pubblicazione: (2024)

Modern predictors and management of incidental prostate cancer at holmium enucleation of prostate
di: Eric V. Li, et al.
Pubblicazione: (2024)

Three‐dimensional ultrastructural and anatomical analysis of prostatic neuroendocrine cells in mice
di: Kei‐Ichiro Uemura, et al.
Pubblicazione: (2024)

Does larger prostate size provide protection for cancer specific outcomes in localized prostate cancer
di: Zain Abedali, et al.
Pubblicazione: (2024)

Real‐world study: Impact of multidisciplinary management of apalutamide‐associated adverse events in prostate cancer
di: Julián Córdoba Sánchez, et al.
Pubblicazione: (2024)

Other‐cause mortality in incidental prostate cancer
di: Francesco Di Bello, et al.
Pubblicazione: (2024)

Cumulative cancer locations on prostate biopsy and active surveillance outcomes in the MRI era
di: Sean A. Fletcher, et al.
Pubblicazione: (2024)

Influence of microbiome in intraprostatic inflammation and prostate cancer
di: Pranav Prakash, et al.
Pubblicazione: (2024)

Cutibacterium acnes invades prostate epithelial cells to induce BRCAness as a possible pathogen of prostate cancer
di: Shingo Ashida, et al.
Pubblicazione: (2024)

A single‐center retrospective review of metastatic prostate cancer on PSMA position emission tomography/computed tomography: Beyond lymph nodes and bones
di: Gabriela N. C. De Jesus, et al.
Pubblicazione: (2024)

FOXA1 regulates ribosomal RNA transcription in prostate cancer
di: Tianwei Jia, et al.
Pubblicazione: (2024)

Translation and validation of a lifestyle questionnaire related to prostate cancer
di: Reyhane Karegar‐Niavol, et al.
Pubblicazione: (2024)

Consistent predictive ability of prostate‐specific antigen density prediction model for clinically significant prostate cancer across age strata
di: Kamil Malshy, et al.
Pubblicazione: (2024)

LGALS3 cfDNA methylation in seminal fluid as a novel prostate cancer biomarker outperforming PSA
di: Irena Abramovic, et al.
Pubblicazione: (2024)

Size and SUVmax define the contribution of nodal metastases to PSA in oligorecurrent prostate cancer
di: Fabian Falkenbach, et al.
Pubblicazione: (2024)

Lower urinary tract symptoms in elderly men: Considerations for prostate cancer testing
di: Stephen Schmit, et al.
Pubblicazione: (2024)

Testosterone bounce predicts favorable prognoses for prostate cancer patients treated with degarelix
di: Shuhei Kamada, et al.
Pubblicazione: (2024)

Development and validation of an imageless machine‐learning algorithm for the initial screening of prostate cancer
di: Nicolas Martelin, et al.
Pubblicazione: (2024)

Outcomes of 10 years of PSA screening for prostate cancer in Norwegian men with Lynch syndrome
di: Eli Marie Grindedal, et al.
Pubblicazione: (2024)

Comparison of abiraterone, enzalutamide, and apalutamide for metastatic hormone‐sensitive prostate cancer: A multicenter study
di: Takafumi Yanagisawa, et al.
Pubblicazione: (2024)

PIK3/Akt/mTOR pathway alterations in metastatic castration‐sensitive prostate cancer
di: Philip Sutera, et al.
Pubblicazione: (2024)

Machine learning and explainable artificial intelligence to predict pathologic stage in men with localized prostate cancer
di: Hemal Semwal, et al.
Pubblicazione: (2024)

An orthotopic prostate cancer model for new treatment development using syngeneic or patient‐derived tumors
di: Naz Chaudary, et al.
Pubblicazione: (2024)

Predicting abiraterone efficacy in advanced prostate cancer: Insights from marker of proliferation Ki67
di: Fengnian Zhao, et al.
Pubblicazione: (2024)

Association of PARP inhibitor treatment on the prevalence and progression of clonal hematopoiesis in patients with advanced prostate cancer
di: Catherine H. Marshall, et al.
Pubblicazione: (2024)

Bellmunt risk score as a survival predictor in patients with metastatic castration‐resistant prostate cancer
di: Thomas Büttner, et al.
Pubblicazione: (2024)

The detection rate for prostate cancer in systematic and targeted prostate biopsy in biopsy‐naive patients, according to the localization of the lesion at the mpMRI: A single‐center retrospective observational study
di: Matteo Massanova, et al.
Pubblicazione: (2024)

Differences in real‐world outcomes by risk classification for localized prostate cancer patients after radiation therapy
di: Lawrence Karsh, et al.
Pubblicazione: (2024)

Impact of presentation timing in metastatic hormone‐sensitive prostate cancer: Characterization of patients and identification of prognostic factors
di: Juliana Arenas Hoyos, et al.
Pubblicazione: (2024)

Incidence and risk factors of prostate cancer among the Northern and Eastern parts of the United Arab Emirates population
di: Jian Wang, et al.
Pubblicazione: (2024)

Targeting proliferating cell nuclear antigen enhances ionizing radiation‐induced cytotoxicity in prostate cancer cells
di: Shan Lu, et al.
Pubblicazione: (2024)

Predicting clinically significant prostate cancer in elderly patients: A nomogram approach with shear wave elastography
di: Xiang Liu, et al.
Pubblicazione: (2024)

A novel HDAC6 inhibitor interferes microtubule dynamics and spindle assembly checkpoint and sensitizes cisplatin‐induced apoptosis in castration‐resistant prostate cancer
di: Pei‐Chen Ye, et al.
Pubblicazione: (2024)

Comparative antiproliferation of human prostate cancer cells by ethanolic extracts of two groups of Brazilian propolis
di: Cleber Silveira MORAES
Pubblicazione: (2010)

Molecular analysis of archival diagnostic prostate cancer biopsies identifies genomic similarities in cases with progression post‐radiotherapy, and those with de novo metastatic disease
di: Philip Vincent Charlton, et al.
Pubblicazione: (2024)

Bimodal imaging: Detection rate of clinically significant prostate cancer is higher in MRI lesions visible to transrectal ultrasound
di: Fabian Falkenbach, et al.
Pubblicazione: (2024)

Impact of proton pump inhibitors on the efficacy of androgen receptor signaling inhibitors in metastatic castration‐resistant prostate cancer patients
di: Tokiyoshi Tanegashima, et al.
Pubblicazione: (2024)

Disrupting prostate cancer research: Challenge accepted; report from the 2023 Coffey‐Holden Prostate Cancer Academy Meeting
di: Andrea K. Miyahira, et al.
Pubblicazione: (2024)

Retrospective analysis of the learning curve in perineal robot‐assisted prostate biopsy
di: Ruth Himmelsbach, et al.
Pubblicazione: (2024)

Real‐world prevalence of adverse events with first‐line systemic therapies among patients with metastatic castration‐sensitive prostate cancer
di: Umang Swami, et al.
Pubblicazione: (2024)